IDEAYA Biosciences (Nasdaq: IDYA) will mark its 10^th anniversary with an in-person and virtual Investor R&D Day.

The Company will share multiple clinical data updates across the pipeline, outline upcoming catalysts and key growth drivers, and review its long-term portfolio strategy.

The event will feature key opinion leader (KOL) Arun D. Singh, MD (Professor of Ophthalmology, Cole Eye Institute, Cleveland Clinic), who will join members of the company’s leadership team.

Agenda topics include:

• IDEAYA 10-Year Anniversary and R&D Day Introduction
• Darovasertib (PKC)
  • Phase 2 Neoadjuvant UM Data in Plaque Brachytherapy-eligible Patients
• IDE849 (DLL3 TOP1 ADC)
  • Phase 1 SCLC Data from the 2025 World Conference on Lung Cancer (WCLC)
  • Mechanistic data from 2025 WCLC to support combination of TOP1-ADCs with IDE161/PARG
• IDE397 (MAT2A)
  • Combination rationale with Trodelvy (TROP2 TOP1 ADC) in MTAP-deletion solid tumors
  • Initial Phase 1 clinical data from IDE397/Trodelvy Combination in MTAP-deletion urothelial cancer
• IDE892 (PRMT5)
  • Potentially best-in-class PRMT5 profile and combination opportunity with IDE397 (MAT2A) in MTAP-deletion solid tumors
• Application of AI/ML in Our Discovery Capabilities

A live analyst question and answer session will follow the formal presentations.